Senior Advisor Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise for the NINDS

COMBINED SYNOPSIS / SOLICITATION (COMPETITIVE) Title: Senior Advisor Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise for the NINDS Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative for the Pain Therapeutics Development Program (PTDP) (i) This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with RFO Part 12. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued. The solicitation number is 7571PSQ00007 issued as a Request for Quote for a Senior Advisor to act as a Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise. The Government reserves the right to make one award, multiple awards, or no awards as a result of this solicitation. This acquisition is set-aside for small business concerns. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at www.acquisition.gov. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (ii) This requirement is for the following services: NINDS is seeking to procure a highly experienced executive-level, drug discovery and development Senior Advisor 2 with extensive expertise in drug discovery and development, in support of the NIH HEAL Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. (iii) Description of requirement: The NIH is seeking to procure a highly experienced executive-level Senior Advisor 2, drug discovery and development subject matter expert with experience in the area of Pharmacology and Pain to provide feedback to the NIH program leadership and technical guidance on drug discovery and development projects within the NINDS HEAL portfolio. The Contractor will serve as a member of the HEAL External Oversight Committee, which will provide strategic guidance on HEAL projects and on occasion other NIH drug discovery and development programs. See Attachment #1 - Statement of Work (SOW) for more information. (iv) The Government anticipates award of a Fixed Price purchase order for this acquisition, and the anticipated base period of performance is: Base: 11/5/2026 – 11/4/2027 Option Year 1: 11/5/2027 – 11/4/2028 Option Year 2: 11/5/2028 – 11/4/2029 (v) The provisions at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this address: https://www.acquisition.gov/far-overhaul https://www.hhs.gov/contract-policies-regulations/hhsar-overhaul (End of provision) a) The following FAR provisions are required by FAR 12.2025(a), and incorporated by reference: • FAR 52.212-1 (Nov 2025) (RFO Deviation), Instructions to Offerors-Commercial Products and Commercial Services. b) The following FAR provisions are required as applicable to this requirement and incorporated by reference: • See Attachment 2 for (Table # 12-2) under FAR 12.205 (a)(3). c) The following HHSAR provisions are applicable to this requirement and incorporated by reference (available upon request): • HHSAR 352.239.78 – Information and Communication Technology Accessibility Notice (FEB 2024) (Deviation) (vi) The clauses at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: https://www.acquisition.gov/far-overhaul https://www.hhs.gov/contract-policies-regulations/hhsar-overhaul (End of clause) a) The following FAR clauses are required by FAR 12.205(b)(1) for all solicitations and incorporated by reference: • FAR 52.212-4 (Nov 2025) (RFO Deviation), Terms and Conditions—Commercial Products and Commercial Services. b) The following FAR clauses are required as applicable to this requirement and incorporated by reference: • See Attachment 3: Table# 12-3. • FAR 52.232-39, Unenforceability of Unauthorized Obligations (Jun 2013). The following HHSAR clauses are applicable to this requirement and incorporated by reference: • HHSAR 352.204-71, Information and Information System Security (FEB 2024) (Deviation). • HSHAR 352-204-73 – Contractor Personnel Security and Agency Access (FEB 2024) (Deviation). • HHSAR 352-239-79 – Information and Communication Technology Accessibility (Feb 2024) (Deviation). FAR/HHSAR PROVISIONS/CLAUSES – FULL TEXT-ADDITIONAL TERMS AND CONDITIONS The following provisions/clauses and additional terms and conditions apply to this acquisition and are provided in FULL TEXT: a) HHSAR 352-237-75 Key Personnel (Oct 2026) (RFO Deviation) - Key personnel specified in this contract are essential to work performance under the contract. The Contractor must obtain the written consent of the Contracting Officer prior to diverting, replacing, or announcing any key personnel substitutions. At least 30 days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts, the Contractor must submit requests for changes in key personnel to the Contracting Officer in writing. The request must identify the circumstances, proposed replacement, a resume and explanation of how the replacement's skills, experience, and credentials meet or exceed the requirements of the contract. When advance notice is not practicable because of termination for cause, other voluntary separation or another circumstance outside the Contractor’s reasonable control, the Contractor must notify the Contracting Officer as soon as practicable. (End of clause) b) FAR 52.217-7, Option for Increased Quantity-Separately Priced Line Item (Mar 1989) The Government may require the delivery of the numbered line item, identified in the Schedule as an option item, in the quantity and at the price stated in the Schedule. The Contracting Officer may exercise the option by written notice to the Contractor within the period of performance of the contract. Delivery of added items shall continue at the same rate that like items are called for under the contract, unless the parties otherwise agree. (End of clause) c) 52.217-9 Option to Extend the Term of the Contract. (a) The Government may extend the term of this contract by written notice to the Contractor within 15 days of contract expiration; provided that the Government gives the Contractor a preliminary written notice of its intent to extend within the period of performance of the contract. The preliminary notice does not commit the Government to an extension. (b) If the Government exercises this option, the extended contract shall be considered to include this option clause. (c) The total duration of this contract, including the exercise of any options under this clause, shall not exceed 3 years. (End of clause) TECHNICAL EVALUATION AND INSTRUCTIONS The Government will evaluate quotations or offers in accordance with RFO FAR 12.203 and award a purchase order from this solicitation to the responsible vendor whose quote conforming to the solicitation will be most advantageous to the Government, price